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Abstract
1. Administration of 14C-Moli1901 (duramycin, 2622U90), a 19 amino acid
polycyclic peptide by intratracheal instillation (approximately 100µg) into the left
cranial lobe of the lung of beagle dogs resulted in retention of 64% of the dose
in the left cranial lobe for up to 28 days.
2. In this study, we used accelerator mass spectrometry (AMS) to quantify
Moli901 following administration of only 0.045µCi of 14C-Moli901 per dog.
Limits of quantitation of AMS were 0.03 (urine) to 0.3 (feces) ng equiv.
Moli1901/g.
3. Whole blood and plasma concentrations of 14C were <5ng/ml at all times
after the dose.  Concentrations of 14C in whole blood and plasma declined over
the first day after the dose and rose thereafter, with the rise in plasma
concentrations lagging behind those in whole blood.  During the first 3 days
after the dose, plasma accounted for the majority of 14C in whole blood, but
after that time, plasma accounted for only 25-30% of the 14C in whole blood.
4. Tissue (left and right caudal lung lobe, liver, kidney, spleen, brain) and bile
concentrations were low, always less than 0.25% the concentrations found in
the left cranial lung lobe.
5. Approximately 13% of the dose was eliminated in urine and feces in 28
days, with fecal elimination accounting for about 10% of the dose.
6. The data presented here are consistent with that obtained in other
species.  Moli1901 is slowly absorbed and excreted from the lung, and it does
not accumulate in other tissues.
7. Moli1901 is currently in the clinic and has proven to be safe in single dose
studies in human volunteers and cystic fibrosis patients by the inhalation route.
No information on the disposition of the compound in humans is available.  This
study in dogs demonstrates the feasibility of obtaining that information using
14C-Moli1901 and AMS.
Introduction
Moli1901, commonly named duramycin,1 is a 19 residue polycyclic peptide
antibiotic (Shotwell et al., 1958, Hayashi et al., 1990) which increases chloride
transport (Cloutier et al., 1990, Cloutier et al., 1993, Molina y Vedia et al., 1996,
Henke et al., 1998) and water mobilization (Molina y Vedia et al., 1996, Henke
et al., 1998) when applied to the apical surface of the airway epithelium.
Because of these properties it may be a useful treatment for cystic fibrosis
(CF), a genetic disease characterized by abnormal chloride ion transport.  This
abnormal chloride transport alters the water content of the airway mucus,
impairing its clearance and leading to infection, inflammation, lung disease and
death.  Moli1901 can increase the chloride permeability in nasal epithelium
from healthy volunteers and CF patients (Zeitlin et al., 2004) and it can
increase the volume of airway surface liquid in normal dogs (Molina y Vedia et
al., 1996, Henke et al. 1998).  The therapeutic goal for the treatment of CF and
other pulmonary diseases like asthma and chronic bronchitis in which the water
content of the mucus is altered, is to remove retained secretions from the
lungs.
The known pharmacokinetic profile of Moli1901 is intriguing. The molecule is
poorly absorbed after inhalation exposure, intratracheal instillation or oral
administration in rats and after oral administration in mice (McNulty et al.,
2003).   The main route of elimination in rats was the feces.  The half-life of
disappearance from the respiratory tract after intratracheal instillation was 64
days and there was no degradation or metabolism of the compound present in
this tissue. The half-life of elimination in the feces in these animals was 52 days
(McNulty et al., 2003).   Plasma and blood concentrations of Moli1901-related
radioactivity were always less than 1ng eq.ml-1 and could not be accurately
measured.  A preliminary study (McNulty et al., 1997) in dogs in which the
animals inhaled aerosolized 3H-labeled Moli1901 provided data suggesting that
absorption from the lung was slow in this species as well.  As in the rat model,
accurate measurements of circulating Moli1901-related material were not
possible in the dog, and the major route of elimination was the feces.
In preparation for determination of Moli1901 disposition in humans, it was
important to determine the systemic exposure to Moli1901-related material in
dogs after exposure via the respiratory tract.  Carbon-14-labeled Moli1901 was
used as a tracer to avoid the possibility of erroneous disposition data due to 3H
exchange.  At the same time, a methodology that would quantify low amounts
of 14C-labeled compound, allowing its application in future human studies was
needed. Accelerator Mass Spectrometry (AMS) is an extremely sensitive and
precise technique for quantifying certain rare, long-lived isotopes such as
carbon-14 and was chosen to quantify the 14C-Moli1901 in this study.  AMS
quantifies isotopic nuclei, rather than radioactive decay, resulting in 103-109 fold
increase in sensitivity compared to the decay counting methods that are widely
employed in radioisotope tracer studies (reviewed by Turteltaub and Vogel,
2000).
In this paper we describe the kinetics, distribution and elimination of 14C-
Moli1901 in beagle dogs after instillation of the dose into the left cranial lobe of
the lung.  14C-Moli1901-related radiocarbon is slowly absorbed, achieves only
very low concentrations in the circulation and major organs, and is slowly
eliminated in the feces.
Materials and Methods
Chemicals.  Unlabeled and 14C-labeled Moli1901 were prepared by Apotex
Fermentation, Inc., Winnipeg, Manitoba, Canada.  The radiolabeled material
was produced by fermentation with 14C-Phe.  The 14C-Moli1901 thus produced
had a radioactive purity of 93% and a specific activity of 3.4mCi/mmol.
Unlabeled and 14C-labeled Moli1901 were mixed to allow a dose of
approximately 100µg of Moli1901 containing about 0.045µCi of 14C-labeled
Moli1901 in 1ml of 0.9% sodium chloride to be given to each dog.
Dose administration.  A total of 12 male beagle dogs, aged 9-10 months were
used in the study.  Anesthetized (isoflurane) dogs were administered the dose
via a tube attached to a bronchoscope that was passed into the caudal portion
of the left cranial lobe of the lung.  Three of the dogs were sacrificed on Day 3
(72 hours after the dose), Day 7 (168 hours after the dose), Day 14 (336 hours
after the dose) and Day 28 (672 hours after the dose).  At the time of sacrifice,
samples of liver, left kidney, spleen, brain, gall bladder bile, left cranial lobe of
the lung, right cranial lobe of the lung and left caudal lobe of the lung were
taken.  Urine and feces were collected daily from the three dogs sacrificed 28
days after the dose.  Blood was collected from all dogs at pre-dose, 2, 4, 8, 12,
24, 48 and 72 hours.  Thereafter, blood was collected from all dogs remaining
at 168, 240, 336, 504, and 672 hours.
Sample collection.  Plasma was separated by centrifugation of samples of
whole blood (collected from the jugular vein).  Blood and plasma samples were
frozen until analysis by AMS.  The weight of each daily urine collection was
recorded, and aliquots were frozen until analysis by AMS.   The weight of each
fecal sample was recorded and the total sample was placed in a plastic bag
and homogenized manually.  Samples were taken and frozen until analysis by
AMS.
Gall bladder bile was collected, and the total volume was recorded.  Samples
were taken and frozen until further analysis by AMS.
The left cranial, left caudal and right cranial lobes of the lung were removed
and weighed.  They were individually flash frozen in liquid nitrogen and
homogenized in a blender with an approximately equal mass of water.  Aliquots
of each lung sample were analyzed by liquid scintillation counting (left cranial
lobe) or AMS (left caudal and right cranial lobes).  For analysis of lung tissue by
liquid scintillation counting, aliquots of each homogenate (ca. 1 g) were
digested with Soluene-350 (Packard Instrument Company, Inc.; Meriden, CT),
neutralized with nitric acid and decolorized with hydrogen peroxide prior to
analysis by liquid scintillation counting (Packard Model 2500TR Liquid
Scintillation Analyzer).  Ultima Gold™ scintillation cocktail (Packard Instrument
Company, Inc.) was used in all determinations of radiochemical content.
All other tissues were homogenized in an approximately equal volume of water.
Aliquots were taken and frozen until analysis by AMS.
Sample analysis.  AMS was used to measure the ratio of 14C to total carbon in
aliquots of whole blood, plasma, urine, feces, bile, liver, kidney, spleen, lung
and brain.  Samples were thawed at room temperature, and an aliquot of each
sample (20 µl blood, 50 µl plasma, 100 µl urine, 10-20 mg feces, 25-50 µl of
bile and homogenate from liver brain, lung, kidney and spleen) were placed in
quartz tubes and dried in a vacuum centrifuge.  The samples were converted to
CO2 by combustion, and the CO2 was quantitatively reduced to graphite in the
presence of zinc and titanium hydride, condensing onto cobalt at approximately
500 ºC for 4 hours (Vogel, 1992, Ognibene et al., 2003).  The carbon ratios of
the graphite samples were then quantified using the 1MV accelerator mass
spectrometer at Lawrence Livermore National Laboratory (Ognibene et al.,
2002).  Between three and seven replicate measurements were recorded for
each sample.  All measurements were normalized to similarly prepared
standards of known carbon isotope ratios.
The carbon ratios of “Time 0 hours” or “Day 0” whole blood, plasma, urine and
fecal samples for each dog were subtracted from the isotope ratios of the other
samples.  No control samples were available for the tissues and bile; hence a
theoretical background carbon ratio of 1.145 Modern was employed.  Excess
14C concentrations were converted to Moli1901 equivalents (parent compound
and all metabolites, if present) using the specific activity of the dose, the
compound molecular weight, and the carbon content of the sample as follows,
where one Modern is equivalent to 98 amol 14C/mg carbon, and the % labeling
of Moli1901 was 1.45.  One amol is 10-18moles; one ag is 10-18g.  The
molecular weight of Moli1901 is 2013.29. All calculations were performed using
Microsoft Excel.
amoles 14C/mg carbon=(Fraction Modern of sample-Fraction Modern of control)
X 98 amoles 14C/mg carbon
amoles 14C/mg tissue=(amoles 14C/mg carbon/100) X % w/w carbon
amoles Moli1901/mg tissue=(amoles 14C/mg tissue) X (100/% labeling of
Moli1901)
ag Moli1901/mg tissue=(amoles Moli1901/mg tissue) X molecular weight
ng Moli1901/g tissue=(ag Moli1901/mg tissue/106)
The carbon content (w/w percentage carbon) was measured using an Exeter
440 CHN Analyzer, using at least 3 replicates for each sample type.  The
average values found and used in calculations were:  plasma--3.3%, whole
blood--11.0%, feces--12.8%, bile--11.8%, kidney--6.1%, spleen--8.3%, brain--
6.4%, liver--7.9%, left caudal lung lobe--5.0% and right cranial lung lobe--4.6%.
As the percentage carbon is more variable in urine (in this study it ranged from
0.2-3.1%), each individual urine sample was analyzed for carbon content.
The limit of quantitation of the AMS analysis is calculated as the mean plus 3
times the SD of the background (i.e., the control samples).  Controls from
whole blood, plasma, urine and feces were used for this calculation.  The limits
of quantitation (ng Moli1901 equivalents/g sample) were calculated as:  whole
blood—0.25, plasma—0.08, feces—0.30, urine—0.03 (based on an average %
carbon of 1.2), bile—0.28, liver—0.19, spleen—0.20, kidney—0.15, left caudal
lung lobe—0.12, right cranial lung lobe—0.11 and brain—0.15.  All samples
contained Moli1901 levels that were well above the limits of quantitation.
Results
Blood and Plasma Concentrations of Moli1901-Related 14C.  At all times
studied after an intratracheal instillation dose of 14C Moli1901, blood and
plasma concentrations of 14C were low (<5ng/ml; table 1).  The concentration of
14C in whole blood declined during the first day after the dose and slowly rose
thereafter.  The concentration of 14C in plasma mirrored the decline and rise
seen in whole blood, although the increase in plasma concentration began
somewhat later (after about 168 hours).  During the first 3 days after the dose,
plasma accounted for the majority of 14C in whole blood, but after that time,
plasma accounted for only 25-30% of the 14C in whole blood.
[Insert table 1 about here.]
Lung Concentrations of Moli1901-Related 14C.  Concentrations of 14C in the
lobe into which 14C-Moli1901 was instilled (left cranial lobe) were high enough
to measure by liquid scintillation counting throughout the 28-day duration of the
experiment (table 2), and the total ng equivalents/g lung remained fairly
constant between 72 and 672 hours.  The percent dose remaining in the lobe
did decrease, however.  This is because the animals got slightly different total
doses due to body weight differences.
[Insert table 2 about here.]
Bile and Tissue Concentrations of Moli1901-Related 14C.  Concentrations of
Moli1901-related 14C in the right cranial and left caudal lung lobes and in bile,
liver, kidney, spleen and brain were much lower than in the left cranial lung lobe
(table 3).  In tissues other than the left cranial lung lobe the highest
concentrations were found in the left caudal lung lobe, and those
concentrations were less than 0.25% of those found in the left cranial lobe.
The next highest concentrations were found in the kidney and right cranial lung
lobe.  Bile and liver had approximately equivalent concentrations, while spleen
had about half the concentration found in liver.  Brain contained only about one-
tenth the concentrations found in spleen.
[Insert table 3 about here.]
Excretion of Moli1901-Related 14C in Urine and Feces.  Approximately 13% of
the dose was eliminated in urine and feces in 28 days (table 4), with fecal
elimination accounting for about 10% of the dose.
[Insert table 4 about here.]
Excretion of Moli1901-related 14C in urine remained fairly constant for
approximately the first 20 days after the dose; between Days 20 and 28
excretion was also constant, but at a higher rate in two of the three dogs (figure
1).
[Insert figure 1 about here.]
Excretion in feces was more rapid during the first four days after the dose than
it was thereafter (figure 2).  From approximately Day 5 through Day 28 fecal
elimination was slow, but constant.
[Insert figure 2 about here.]
Discussion
The data in this paper are consistent with those reported previously for rats,
mice and dogs (McNulty et al., 1997, 2003) in that Moli1901-related material
disappears slowly from lungs after an inhalation or instillation dose, and it is
slowly excreted, primarily in the feces.  Based on earlier data (McNulty et al.,
1997, 2003) it is probable that little or no metabolism of Moli1901 occurred.  It
is quite likely that most of the Moli1901-related material appearing in the feces
is the result of swallowing the compound subsequent to mucociliary clearance
from the lungs.
Of the tissues examined, excluding the site of administration, kidney and lung
contained the highest concentrations of Moli1901-related material.  In rats
given an intravenous dose of the compound (McNulty et al., 2003), the highest
concentrations were found in spleen and liver.  No explanation for this
difference in distribution of absorbed Moli1901-related material is readily
apparent from the data gathered.
The concentration of Moli1901-related material in blood and plasma declined at
first and then rose toward the end of the experimental period.  This suggests
that the compound was being removed more slowly from blood than it was
being added by absorption from the lung or from the gastrointestinal tract after
swallowing (see above).  Furthermore, as the time after the dose increased, so
did the proportion of Moli1901-related material associated with the cellular
fraction of blood.  Several studies have shown that Moli1901 interacts with
membrane phospholipids (Navarro et al., 1985, Sokolove et al., 1989). The
NMR analysis from Wakamatsu et al. (1990) indicates that a biological analog
to Moli1901 named Ro90198 differing only in one residue (Lys present in
Moli1901 is replaced by Arg in Ro90198) binds to the polar head of
phosphatidyl ethanolamine (PE).  We have confirmed that Moli1901 possesses
this same property (Molina, unpublished data).  In addition, Choung et al.
(1988) and Aoki et al. (1994) have characterized the binding of Ro90198 to
human erythrocytes and demonstrated that the peptide binds to PE and could
induce its outward transbilayer movement. Similarly, we anticipate binding of
Moli1901 to the PE present in the red blood cells.  It is even conceivable that
these cells would concentrate compound present in plasma. This may be due
to the association of Moli1901 with cell membranes in whole blood.
A similar association with membrane lipids may account for the slow removal of
Moli1901-related material from the site of application in the lung.  Alternatively,
the slow removal of the compound from the lung may be due to the size and
molecular weight of Moli1901 limiting its absorption.  While peptides with more
amino acid residues such as insulin (51 residues) and growth hormone (192
residues) can be absorbed from the lungs of humans and animals in active
form (reviewed in Patton and Platz, 1992), the structure of Moli1901 differs
from those molecules in having several intramolecular bonds.  These
intramolecular bonds may force the compound into retaining a 3-dimensional
structure with a greater molecular radius than insulin or growth hormone.
Studies of model peptide transport across rat alveolar cell monolayers have
demonstrated that absorption is primarily paracellular and is inversely related to
molecular radius (Dodoo et al., 2000).
The data in this study are consistent with data in the previous study of inhaled
aerosolized 3H-Moli1901 in dogs.  In both studies, a significant portion (50-
65%) of the dose of radiolabel remained in lung tissue at 4 weeks after dose
administration, although in the earlier study, the radiolabel was more evenly
distributed in lung tissue.  This is an expected result given that the dose was
delivered to all lobes of the lung in that study.  In both studies fecal elimination
was the primary route of excretion, and the bulk of the fecal excretion occurred
over the first couple of days.
Moli1901 is currently in the clinic and has proven to be safe in single dose
studies in human volunteers and CF patients by the inhalation route.  Although
technically challenging, determination of the half-life or residence time in the
lung, as well as the biodistribution and excretion are long term goals of the
project. This study in dogs demonstrates the feasibility of the execution of a full
clinical protocol using 14C-Moli1901 and AMS to attain those objectives.
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Footnotes
1 Moli1901 is used throughout to denote the compound studied.  It has also
been known as 2262U90 and duramycin; those names are used in some of the
cited material.
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Table 1:  Average concentrations of Moli1901-related 14C in blood and plasma
Concentration
(ng equiv/ml)
Time (hr) Blood Plasma
2 3.24±0.85a 4.98±0.88a
4 2.15±0.57a 3.33±0.69a
8 1.23±0.18a 2.34±0.34a
12 1.02±0.20a 1.96±0.28a
24 1.02±0.22a 1.78±0.28a
48 1.10±0.24a 1.54±0.27a
72 1.20±0.26a 1.42±0.24a
168 1.59±0.22b 1.19±0.17b
240 1.75±0.28c 1.04±0.07c
336 1.92±0.29c 1.03±0.11c
504 2.28±0.21d 1.18±0.11d
672 2.58±0.77d 1.46±0.07d
Values are mean±SD.
aN=12
bN=9
cN=6
dN=3
Table 2:  Percent dose and concentrations of Moli1901-related 14C remaining in the left
cranial lung lobe at various times after dose administration
Time
(hr)
% dose
in lobe
ng equiv/g
in lobe
72 73.4±4.4 34911±6076
168 65.3±3.8 46981±1622
336 69.8±4.9 46370±3293
672 64.1±9.4 47659±5232
Values are mean ±SD; N=3.
Table 3:  Average concentrations of Moli1901-related 14C in bile and tissues at various
times after the dose.
Concentration (ng equiv/g) in:
Time
(hr) Bile Liver Kidney Spleen Brain
Lung,
right
cranial
lobe
Lung, left
caudal lobe
72 8.03±0.41 6.67±2.87 20.15±1.55 4.83±3.84 0.43±0.04 10.24±7.34 28.04±26.66
168 9.65±2.37 10.71±4.35 16.74±3.02 4.50±1.71 0.54±0.11 10.68±6.61 42.01±30.17
336 5.30±1.05 9.93±2.96 16.37±0.56 6.25±3.84 0.48±0.02 9.51±7.93 25.05±21.43
672 15.31±3.41 6.46±0.66 18.81±1.92 3.37±0.15 0.64±0.08 4.17±0.78 20.71±12.35
Values are mean ±SD; N=3.
Table 4:  Cumulative Excretion of Moli1901-related 14C in urine and feces.
Dog #
% dose
in urine
% dose
in feces
352 3.7 11.9
353 2.8 10.0
395 2.0 8.6
averagea 2.8±0.8 10.2±1.6
 aAverage of all three dogs±SD.
Figure 1:  Cumulative excretion of Moli1901-related 14C in urine.
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Figure 2:  Cumulative excretion of Moli1901-related 14C in feces.
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